Cargando…

First Results of Concurrent Chemoradiation with Two Courses of 5 × 25 mg/m(2) Cisplatin for Locally Advanced Head and Neck Cancer

Many patients with squamous cell carcinoma of the head and neck (SCCHN) receive cisplatin-based chemoradiation. Cisplatin 100 mg/m(2) every three weeks is toxic and alternative cisplatin regimens are desired. Two courses of 20 mg/m(2)/day 1–5 (cumulative 200 mg/m(2)) were shown to be similarly effec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwaan, Inga, Soror, Tamer, Idel, Christian, Pries, Ralph, Bruchhage, Karl L., Hakim, Samer G., Yu, Nathan Y., Rades, Dirk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10300787/ https://www.ncbi.nlm.nih.gov/pubmed/37373994 http://dx.doi.org/10.3390/jpm13061006

Ejemplares similares

Chemoradiation with Cisplatin vs. Carboplatin for Squamous Cell Carcinoma of the Head and Neck (SCCHN)
por: Rades, Dirk, et al.
Publicado: (2023)

A New Prognostic Instrument for Predicting the Probability of Completion of Cisplatin during Chemoradiation for Head and Neck Cancer
por: Rades, Dirk, et al.
Publicado: (2023)

Smoking-, Alcohol-, and Age-Related Alterations of Blood Monocyte Subsets and Circulating CD4/CD8 T Cells in Head and Neck Cancer
por: Idel, Christian, et al.
Publicado: (2022)

Salvage High-Dose-Rate Interventional Radiotherapy (Brachytherapy) Combined with Surgery for Regionally Relapsed Head and Neck Cancers
por: Soror, Tamer, et al.
Publicado: (2023)

Increased Abundances of CD16(+) Non-Classical Monocytes Accompany with Elevated Monocytic PD-L1 and CD4(+) T Cell Disturbances in Oropharyngeal Cancer
por: Idel, Christian, et al.
Publicado: (2022)

Impact of a mobile application (reminder app) on acute toxicity during radiotherapy of head-and-neck cancer – results of a randomized phase III trial (RAREST-02)
por: Rades, Dirk, et al.
Publicado: (2022)

TRIM21 Expression as a Prognostic Biomarker for Progression-Free Survival in HNSCC
por: von Bernuth, Amelie, et al.
Publicado: (2023)

Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m(2) for definitive radiochemotherapy of locally advanced head-and-neck cancers
por: Rades, Dirk, et al.
Publicado: (2016)

Plasma‑derived CD16 exosomes and peripheral blood monocytes as correlating biomarkers in head and neck cancer
por: Theodoraki, Marie-Nicole, et al.
Publicado: (2023)

Primary Concurrent Chemoradiation in Head and Neck Cancers with Weekly Cisplatin Chemotherapy: Analysis of Compliance, Toxicity and Survival
por: Iqbal, Muhammad Shahid, et al.
Publicado: (2016)

Spatial Distribution of Immune Cells in Head and Neck Squamous Cell Carcinomas
por: Idel, Christian, et al.
Publicado: (2021)

Concurrent Chemoradiation with Low-Dose Weekly Cisplatin in Locally Advanced Stage IV Head and Neck Squamous Cell Carcinoma
por: Kang, Myoung Hee, et al.
Publicado: (2015)

ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation
por: Jun, H J, et al.
Publicado: (2008)

Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin
por: van der Vorst, Maurice J. D. L., et al.
Publicado: (2019)

Comparing high‐dose cisplatin with cisplatin‐based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC)
por: Furqan, Muhammad, et al.
Publicado: (2019)

Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells
por: Möckelmann, Nikolaus, et al.
Publicado: (2016)

Phase II trial of individualized/dynamic cisplatin regimens for definitive concurrent chemoradiation therapy in patients with head and neck squamous cell carcinoma
por: Ahn, Dongbin, et al.
Publicado: (2020)

Performance of Different Diagnostic PD-L1 Clones in Head and Neck Squamous Cell Carcinoma
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

Concurrent Chemoradiation for Vaginal Cancer
por: Miyamoto, David T., et al.
Publicado: (2013)

Assessment of the Role of Gefitinib With Concurrent Chemoradiation in Locally Advanced Head and Neck Cancer
por: Prajapati, Raju, et al.
Publicado: (2022)

Matched pair analysis for comparison of survival outcome of alternative regimens to standard three-weekly cisplatin-based concurrent chemoradiation of head and neck cancer
por: Han, Hye Ri, et al.
Publicado: (2021)

CDK7 Predicts Worse Outcome in Head and Neck Squamous-Cell Cancer
por: Jagomast, Tobias, et al.
Publicado: (2022)

Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
por: Kong, Tae Wook, et al.
Publicado: (2012)

Comparison of standard-dose 3-weekly cisplatin and low-dose weekly cisplatin for concurrent chemoradiation of patients with locally advanced head and neck squamous cell cancer: A multicenter retrospective analysis
por: Lee, So Yeon, et al.
Publicado: (2018)

A Unique Complication Associated with Concurrent Chemoradiation for the Treatment of Locally Advanced Head and Neck Cancer
por: Cahlon, Oren, et al.
Publicado: (2008)

The Lived Experiences of Patients with Head and Neck Cancer during Concurrent Chemoradiation Therapy Care Process
por: Kongwattanakul, Sirikorn, et al.
Publicado: (2020)

Concurrent chemoradiation with carboplatin for locally advanced cervical cancer at high-risk for developing cisplatin-induced renal dysfunction
por: Cetina, Lucely, et al.
Publicado: (2007)

Salvage high-dose-rate interventional radiotherapy (brachytherapy) for locally relapsed prostate cancer after radical prostatectomy and subsequent external irradiation
por: Soror, Tamer, et al.
Publicado: (2023)

CDK19 as a Potential HPV-Independent Biomarker for Recurrent Disease in HNSCC
por: Paulsen, Finn-Ole, et al.
Publicado: (2020)

NR2F6 as a Prognostic Biomarker in HNSCC
por: Klapper, Luise, et al.
Publicado: (2020)

TRIM24 Expression as an Independent Biomarker for Prognosis and Tumor Recurrence in HNSCC
por: Klapper, Luise, et al.
Publicado: (2022)

Immunologic “Cold” Squamous Cell Carcinomas of the Head and Neck Are Associated With an Unfavorable Prognosis
por: Ribbat-Idel, Julika, et al.
Publicado: (2021)

Association of cytochrome P450 2C9 polymorphism with locally advanced head and neck squamous cell carcinoma and response to concurrent cisplatin-based radical chemoradiation
por: Paul, Sayan, et al.
Publicado: (2014)

Prognostic impact of the loss of E-cadherin and de novo expression of N-cadherin at the invasive front of primary and recurrent oral squamous cell carcinoma
por: Hakim, Samer George, et al.
Publicado: (2023)

A prospective comparative study between concurrent chemoradiation with brachytherapy boost with concurrent chemoradiation alone in locally advanced cancer esophagus
por: Tudu, Rajanigandha
Publicado: (2020)

A prospective randomized study comparing concurrent chemoradiation with weekly and 3 weekly cisplatin in locally advanced oropharyngeal carcinoma
por: Nanda, R., et al.
Publicado: (2019)

Cisplatin induced cerebral sinus venous thrombosis in cervical cancer patients treated with concurrent chemoradiation: a case series
por: Valiyaveettil, Deepthi, et al.
Publicado: (2021)

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once‐a‐week versus once‐every‐3‐weeks cisplatin
por: Menon, Nandini S., et al.
Publicado: (2022)

Modes of Action of 1,8-Cineol in Infections and Inflammation
por: Pries, Ralph, et al.
Publicado: (2023)

Complete remission in very advanced oral cancer by docetaxel, cisplatin, 5-fluorouracil based induction chemotherapy followed by concurrent chemoradiation
por: Chiang, Tien-En, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d3ti0ugj1p2477lq63dvsukc39